Bleeding and Thromboembolic Events in Patients With HeartMate II Mechanical Circulatory Support by Allana, Salman et al.
 
 
 
 
The VAD Journal: http://dx.doi.org/10.13023/VAD.2016.07   Page 1 of 16 
 
The VAD Journal: The journal of mechanical assisted circulation and heart failure 
Peer-Reviewed Original Research 
Bleeding and Thromboembolic 
Events in Patients with Heartmate II 
Mechanical Circulatory Support 
Salman S. Allana, Carrie B. Chapman, Nancy K. Sweitzer,  
Maryl R. Johnson, Takushi Kohmoto, Margaret Murray,  
David Murray, Zhanhai Li, Peter S. Rahko* 
 
Cardiovascular Medicine Division, Department of Medicine 
and Cardiothoracic Surgery Division, Department of Surgery 
University of Wisconsin School of Medicine and Public Health 
 
* Corresponding author: psr@medicine.wisc.edu 
 
Abstract 
 
Background  
 
Bleeding and thromboembolic events (TE) are common complications following 
HeartMate II (HMII) implantation.  The aim of the study was to review our 
experience related to bleeding and TE events in patients with a HMII and identify 
factors associated with increased risk of these events. 
 
Methods 
We retrospectively reviewed 70 consecutive patients who received a HMII 
between May 2006 and December 2011.  The patients were followed for 12 
months or until cardiac transplantation, device explantation or death.  Major 
bleeding was defined by INTERMACS criteria with intracranial bleeding events 
added.   
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Results 
There were 48 bleeding events in 28 (40%) patients with gastrointestinal 
bleeding (54.2%) being most common.  Patients with bleeding events had 
significantly higher average INR (p=0.04) and more chronic kidney 
disease (p=0.03), although 43.8% of bleeding events occurred at an INR 
<2.  Twelve TE events occurred in 9 patients (12.9%), with ischemic 
stroke the most common (75%).  TE events were associated with young 
age (p=0.04) and non-diabetes status (p=0.03) and were not associated 
with average INR.  There was no association of bleeding or 
thromboembolism with gender, BMI, HMII speed, pulsatility index, 
hypothyroidism, smoking history or INTERMACS profile at the time of 
HMII implantation. 
Conclusion 
Different factors are associated with bleeding and TE events.  The 
appropriate target INR range for HMII patients should be chosen to 
balance the risk between bleeding and TE events based largely on patient 
factors.  
Keywords 
mechanical circulatory support; ventricular assist device; heart failure; 
bleeding events; thromboembolic events 
Abbreviations 
 
HF = Heart Failure 
NYHA = New York Heart Association  
MCS = Mechanical Circulatory Support 
HMII = HeartMate II 
DM = Diabetes Mellitus 
CKD = Chronic Kidney Disease 
GFR = Glomerular Filtration Rate 
vWF = von Willebrand Factor 
HMWM = High Molecular Weight Multimers 
PI = Pulsatility Index 
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Introduction 
 
The burden of heart failure (HF) continues to grow, with over 500,000 cases 
annually1 and increasing numbers of hospitalizations.  With pharmacological and 
device-based therapies, 1 year mortality of HF patients with New York Heart 
Association class (NYHA) III and IV has decreased from 50% in 1986 to less 
than 15% in 2002.1-5  Despite these advances, many patients with advanced HF 
continue to have severe symptoms.1   
 
In the last 15 years, implantation of mechanical circulatory support (MCS) has 
been demonstrated to prolong survival and improve quality of life.1  Continuous 
flow MCS can be used as destination therapy and bridge to recovery or 
transplantation.6  The HeartMate II (HMII) by Thoratec Corporation, Pleasanton, 
CA is one such continuous-flow device that has become the most commonly 
used device for MCS in end-stage HF patients.  However, there are still 
substantial risks and complications during the implant period and with long term 
HMII support.  
 
Thromboembolic events occur with the use of HMII despite the use of 
anticoagulation and antiplatelet therapies.  This, in turn, is thought to contribute 
to increased bleeding events in these patients.  Indeed, bleeding complications 
with the HMII are more common than thromboembolic events,7 with its incidence 
varying widely between studies and influenced by the definition of bleeding used.  
Bleeding was reported in 15.4% of patients in the HMII bridge to transplant trial.8  
Uriel et al in 2010 reported bleeding to occur in as high as 44.3% of the patients 
receiving HMII.9  In patients who undergo mechanical valve replacement, where 
a targeted INR is required, bleeding rates of only 2.68 to 4.6 events/100 patient 
years are seen.10  In contrast, continuous flow MCS patients have been shown to 
experience bleeding rates as high as 63 events/100 patient years.11  Therefore, 
these events must be attributed to factors other than the use of anticoagulation 
and antiplatelet therapies.  A universal loss of high molecular weight multimer 
(HMWM) has been reported in continuous flow MCS recipients.12  Development 
of acquired von Willebrand syndrome due to loss of HMWM appears to be a 
potential contributor to the bleeding tendencies in HMII recipients.13  In the 
present study we review our experience related to the bleeding and 
thromboembolic events in patients with HMII implantation and explore factors 
associated with this increased risk.  
 
Methods 
 
Patients and Study Design 
 
This study is a retrospective chart review of 70 consecutive subjects in whom a 
HMII MCS was implanted between May 2006 and December 2011 at the 
University of Wisconsin Hospital and Clinics, Madison, WI.  The study was 
approved and complied with all regulations of the University of Wisconsin 
Institutional Review Board and the Veterans Affairs Research & Development 
Committee.  Baseline and demographic data were collected including age, 
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gender, body mass index, HF etiology, NYHA class, history of diabetes mellitus 
(DM) and chronic kidney disease (CKD).  CKD was defined as glomerular 
filtration rate (GFR) <60 mL/min/1.73 m2 for at least 3 months.  Subjects were 
categorized by whether HMII was placed as a bridge to transplantation, bridge to 
candidacy or as destination therapy.  The subjects were followed every 6-12 
weeks for 12 months or until cardiac transplantation, device explantation or 
death.  Major bleeding episodes were defined by the INTERMACS criteria14 as 
any internal or external bleeding event that results in death, hospitalization, 
reoperation or red blood cell transfusion (greater than or equal to 4 units within 
first 7 days post implant and any number of units after 7 days post implant).  
Intracranial bleeding was also included as a major bleeding episode in this 
analysis, although it was classified as a neurological event in INTERMACS.  
Thromboembolic events were defined by any arterial thromboembolic events 
including ischemic stroke and confirmed pump thrombosis. The HMII pump 
speed, pulsatility index (PI), flow and power were recorded at the time of the 
implantation, at 1, 2 and 3 months post implantation and every 3 months 
thereafter.  
 
Clinical assessment and echocardiographic parameters were used to adjust the 
HMII speeds to optimize cardiac output, achieve adequate left ventricular 
decompression, avoid suction events, maintain target pulsatility index and 
provide aortic valve opening every 2-3 beats when possible.  Pump speed was 
set between 8600 and 10000 rotations per minute (rpm) according to these 
factors.  All patients were on a HF medication regimen titrated to maintain mean 
blood pressures <85 mmHg and optimize perfusion based on clinical 
assessment.  
 
Anticoagulation therapy  
 
Low dose aspirin and anticoagulation therapy with warfarin was started on post-
operative day 2 or 3.  INR was maintained between 2 and 3.  No post-operative 
heparin was given. For purposes of this study patients’ INRs were recorded at 1, 
2 and 3 months’ post hospital discharge, every 3 months thereafter and when 
patients presented with a bleeding or a thromboembolic event.  INR at the time of 
bleeding and thromboembolic events was recorded.  Also, average INR was 
calculated by taking the mean of all the INR values from the time the INR first 
became therapeutic after the HMII placement till the bleeding event.   
 
Statistical Analysis 
 
Statistical analysis was performed using SPSS version 19.0.  Continuous data 
were compared using the t-test and presented as mean and standard deviation.  
Categorical data were analyzed using the chi square or the Fischer exact test.  
Results were considered statistically significant for a p value less than 0.05.  We 
also used repeated measure analysis with binary outcome to test the effect of 
average PI on bleeding events adjusting for months since implant, age and 
gender.  Using a binary outcome analysis, we model the odds of a “success” 
(bleeding event), p(x)/(1-p(x)).  The slope=b means that the odds increase 
multiplicatively by exp(b) for every one-unit increase in the predictor, PI. 
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Results 
 
Demographics 
 
The baseline characteristics of the population are shown in Table 1.  The 
INTERMACS profiles of the patients are shown in Figure 1. 
 
Table 1.  Baseline Characteristics of the Study Population  
 
 
 
Average follow up was 238+/-168 days with a total of 45.6 patient-years of follow 
up.  Fifteen patients (21.4%) completed 12 months of post device implantation 
follow up without transplantation, device explant or death; 39 (55.7%) underwent 
cardiac transplantation and 15 (21.4%) died.  One patient developed HMII 
dysfunction with mediastinal hematoma after a fall, requiring device explantation, 
and was not re-implanted due to recovery of left ventricular function.  
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Figure 1 Percentage of study patients (y axis) in various INTERMACS  
profiles (x axis) 
 
Bleeding  
 
There were 48 bleeding events in 28 patients.  Six of these (21.4%) occurred in 
women.  Average age was 56.3+/-9.9 years.  Blood transfusion was necessary in 
27 (56.3%) bleeding events with an average of 2.1+/-2.6 units of packed red cells 
per event (range of 0-12 units, interquartile range of 0-4 units with 0 and 4 the 
25th and 75th percentile respectively and median of 2 units per event).  
Gastrointestinal bleeding was the most common bleeding event.  Intracranial 
bleeding occurred in 6 patients and had a case fatality rate of 50%.  Traumatic 
bleeding occurred in four patients causing mediastinal hematoma, lower 
extremity hematoma, hemothorax and acute subdural hematoma occurring in 
one patient each.  There were no post-surgical bleeding events.  Five bleeding 
events resulted in death and 5 required major surgical interventions (laparotomy 
in 2 and craniotomy, thoracotomy and lower extremity debridement in 1 patient 
each).  Bleeding events and their outcomes are summarized in Table 2.  
  
Many bleeding events, 21 of 48 (43.8%), occurred at an INR level of less than 2; 
19 (39.5%) at INR between 2 and 3 and 8 (16.7%) at an INR greater than 3 
(Figure 2).  
 
Table 2. Bleeding Events and their Outcomes 
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Figure 2 Percentage of bleedings and thromboembolic events  
(y axis) against INR (x axis) 
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Table 3 shows clinical characteristics of patients with bleeding compared to those 
without.  Patients with bleeding events tended to be older and had significantly 
higher average INR than patients without bleeding events.  Eighteen of 28 
(64.2%) patients with bleeding events had CKD as compared to 16 of 42 (38.1%) 
without bleeding events (p=0.03).  Greater proportion of females experienced a 
bleeding event as compared to males (46% vs 38.6%), although this result was 
not statistically significant. 
 
Table 3.  Comparison of Characteristics of Patients with and without 
Bleeding Events 
 
 
 
 
Bleeding was not associated with HMII speed, body mass index pre HMII 
implantation, HF etiology, DM, hypothyroidism, smoking status or pre-operative 
INTERMACS profile.  We also analyzed bleeding events with the average home 
PI and PI recorded at each clinic visit.  Bleeding events were not associated with 
average home PI (slope of - 0.04 +- 0.29, p=0.88) or the clinic PI value (slope of 
0.12+-0.35, p=0.72).  Average time to a bleeding event was 109 +/- 115 days 
with 34 (70.4%) events occurring within 4 months of device implantation (Figure 
3).  
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Figure 3: Cumulative percentage of bleeding and thromboembolic  
events (x axis) over time in months (y axis) 
 
Thromboembolic Events 
 
There were 12 thromboembolic events in 9 patients.  All were males except one.  
Most events, 8 of 12 (66.7%), occurred at an INR of <2 and 4 (33.3%) at an INR 
between 2 and 3.  None of the thromboembolic events occurred with INR >3 
(Figure 2).  Ischemic stroke was the most common thromboembolic event (Table 
4). 
 
Table 4.  Thromboembolic Events and their Outcomes 
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Table 5 presents the clinical characteristics of patients with and without 
thromboembolic events.  Patients who had thromboembolic events were 
significantly younger that those who did not.  Thromboembolic events were not 
found to be associated with body mass index, HMII speeds, average INR, HF 
etiology, hypothyroidism, smoking history, CKD, gender or preoperative 
INTERMACS profile.  Non-diabetics comprised 88.9% (8 out of 9) of the patients 
who had a thromboembolic event as compared to 49.2% who did not, suggesting 
thromboembolic events to be more common among non-diabetics (p=0.03).  
Average time to a thromboembolic event was 130+/-140 days with 7 out of 12 
events (58.3%) occurring in less than 90 days (Figure 3). 
 
Table 5.  Comparison of Characteristics of Patients with and without 
Thromboembolic Events 
 
 
 
Discussion 
 
The HMII is currently the most widely used long term mechanical circulatory 
support device, with more than 7,000 implantations and more than 3,000 patients 
on support.15  It is associated with significant improvement in 2 year survival free 
of stroke and device failure compared with pulsatile MCS.7  Advantages of HMII 
include its reduced size, increased durability, ease of implantation, and reduced 
infections.9  However, complications can accompany the use of HMII, the most 
significant of which are bleeding and thromboembolic events.  
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With varying definitions of bleeding, bleeding rates as high as 44.4% have been 
reported in patients with HMII.9  In our study, 40% of the patients had one or 
more bleeding events. Using a similar definition of bleeding as in our study, 
Bunte et al16 reported occurrence of bleeding in 58% of the population.  Notably 
this study also had a high rate of post-operative bleeding and classified anemia 
of undetermined source as a bleeding event.  The average INR in the bleeding 
population in our study was significantly higher than the non-bleeding population, 
even though both values were in the therapeutic range of 2-3.  This reinforces 
that a higher level of anticoagulation contributes to bleeding events.  Keeping 
INR in the low therapeutic range may decrease the frequency of bleeding.  
However, nearly half the bleeding events in our population occurred at INR of <2.  
This suggests that average INR over a period of time may be a better marker of 
bleeding than the INR at the time of the event.  Patients on chronic long term 
anticoagulation secondary to mechanical valve replacement or atrial fibrillation 
and HF patients on anticoagulation have far lower bleeding rates than those 
observed in continuous flow MCS populations.  The WATCH trial (Warfarin and 
Antiplatelet Therapy in Heart Failure Trial)17 that examined the role of 
anticoagulation in HF patients revealed rates of bleeding on warfarin at 5.2%, 
significantly lower than observed in our series.  Similar results were reported in 
the WASH (Warfarin/Aspirin Study in Heart Failure) and HELAS (Heart Failure 
Long Term Antithrombotic Study) studie.18,19  These data suggest presence of 
additional factors contributing to bleeding events in MCS patients.   
 
Recent studies have supported a contribution of acquired von Willebrand 
deficiency to bleeding events in continuous flow MCS patients.9,20-22  HMII 
patients experience altered physiology due to the high shear stress associated 
with blood flow through the impeller.  This shear stress is hypothesized to result 
in vWF conformation changes that lead to proteolysis and cleavage of the 
HMWM by ADAMTS13.23  Uriel et al9 and Meyer et al22 reported decreased or 
absent HMWM forms of vWF in all patients with HMII in their studies.  Similar 
results were produced in a recent study that showed decrease of 30+/-14% of 
HMWM of vWF in patients with HMII compared to normal plasma levels.24  
However, not all these patients had bleeding events, possibly suggesting a 
multifactorial etiology.  
 
Gastrointestinal bleeding was the most common cause accounting for bleeding in 
22.3% of all the study patients.  This is in accordance with the other studies.9,25,26  
Although the most common etiology, only 1 patient died secondary to a major 
gastrointestinal bleed.  Gastrointestinal bleeding likely results from factors 
besides anticoagulant therapy and acquired vWF deficiency.  Older patients tend 
to have more colonic polyps, increasing the risk of colonic bleeding.  In patients 
with HMII the left ventricle is relatively decompressed, with minimal opening of 
the aortic valve creating flow patterns similar to those with aortic stenosis.  Heyde 
et al27 suggested that the abnormal pulse wave associated with aortic stenosis 
may cause distention of the sub-mucosal venous plexuses of the gastrointestinal 
tract and eventually lead to angiodysplasia and arteriovenous malformations.27  
Cessation of gastrointestinal bleeding has been reported in continuous flow MCS 
patients after cardiac transplantation.28 
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Most bleeding events (70.4%) occurred in the first 4 months of HMII implantation.  
Bunte et al16 also showed cumulative incidence of bleeding peaking within the 
first 3 months.  There was no post-surgical bleeding requiring re-sternotomy in 
these patients, although the reported incidence of this varies from 10-30% in 
literature.7,29-31  Previous studies have suggested age as an important risk factor 
for bleeding after MCS.9,26,30  Boyle et al32 determined age >65 a risk factor for 
increased bleeding in this population.  Uriel et al9 showed that the risk of bleeding 
for a patient >66 years was 65%.  Our study had only 5 patients (7.1%) who were 
greater than 65 years of age with a non-significant trend toward increased 
bleeding in older patients.  In our study, bleeding events were more common in 
patients with CKD.  Only 3 patients (10.7%) had 6 bleeding events while on some 
form of hemodialysis (chronic hemodialysis or continuous veno-venous 
hemofiltration).  Administration of heparin or sodium citrate during the 
hemodialysis can contribute to bleeding, however, does not explain association 
of bleeding with CKD as the proportion of patient on hemodialysis was small.  
Bleeding can also be attributed to platelet dysfunction due to decreased platelet 
aggregation and impaired platelet adhesiveness in CKD.33  The impairment in 
platelet adhesiveness may result at least in part from intrinsic dysfunction of 
glycoprotein IIb/IIIa, a platelet membrane glycoprotein that plays a major role in 
platelet aggregation and adhesion by interacting with fibrinogen and vWF.34-36  
 
Boyle et al32 reported female gender as a risk factor for bleeding events.  In our 
study although the incidence of bleeding was higher in females, this result was 
not statistically significant, likely due to a small proportion of female population in 
the study.  We also hypothesized that increased HMII speed would be associated 
with increased bleeding events.  Increased speed would decompress the left 
ventricle and result in decreased opening frequency of the aortic valve with flow 
patterns similar to those observed in aortic stenosis and predisposing to 
gastrointestinal arteriovenous malformations.  Higher speeds would also 
theoretically expose red cells to increased shear stress and increase severity of 
acquired von Willebrand syndrome.  However, in our study there was no 
association of bleeding with HMII speeds.  
 
We examined the association of bleeding with PI.  It has been hypothesized that 
decreased PI may lead to arteriovenous malformations and thus an increased 
risk of bleeding through a similar mechanism to the Heyde syndrome in aortic 
stenosis.27  Wever-Pinzon et al37 reported low PI to be associated with increased 
risk of non-surgical bleeding during the first 3 months after implantation of HMII.  
We, however, did not find any association between bleeding events and PI.  
 
Recent data suggests that the bleeding risk of continuous flow MCS support may 
be offset by minimizing the use of anti-coagulation.38  However, pump thrombus 
and embolic cerebrovascular accidents remain a concern.  In our study, the level 
of INR was not statistically different in patients with and without thromboembolic 
events.  However, 66.7% of all the thromboembolic events occurred at INR of 
less than 2 and none of the events occurred at an INR greater than 3.  This 
sheds light on the efficacy of anticoagulant therapy to prevent these events in 
patients with the HMII.  Boyle et al8 reported thromboembolic events in 3.3% of 
the population with HMII, a lower rate than that found in our study.  Similar lower 
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rates have been reported in comparable cohorts in other studies.15,39  it is also 
important to note that the advanced heart failure population has an inherent risk 
of thromboembolic stroke.  In the Randomized Evaluation of Mechanical 
Assistance in Treatment of Chronic Heart Failure (REMATCH) trial, patients 
assigned to optimal medical therapy had a yearly stroke rate of 5.2%.5 
 
A recent study found significantly increased incidence of thrombotic 
complications in females;32 however, in our study gender was not associated with 
thromboembolic events.  Interestingly, in our study, thromboembolic events were 
more common in younger patients and in non-diabetics.  In clinical experience, 
younger patients are seen to be less compliant with medications and also have 
better inflammatory and clotting cascades that may account for this result.  
Association of thromboembolic events with non-diabetes status is curious but this 
could be a cofactor as young patients are less likely to have underlying diabetes 
mellitus.  It appears in our data and the literature that younger patients are more 
likely to have thromboembolic events and older patients more likely to bleed; a 
possible implication would be that INR goals be tailored to patient age.  However, 
further studies are needed to confirm this hypothesis.  
 
Recently, Starling et al reported occurrence of pump thrombosis to be 7.5% 
during 12 months of support, and 12.3% during 24 months of support with HMII.40  
In our study, only one patient developed pump thrombosis (1.4%). 
 
Conclusion  
 
Our study confirms that thrombotic events in patients implanted with continuous 
flow MCS are significantly overshadowed by the frequency of hemorrhagic 
events.  We did not find any association of the bleeding or thromboembolic 
events with HMII speed, body mass index, HF etiology, hypothyroidism, smoking 
status or pre-operative INTERMACS profile.  Bleeding events are associated with 
chronic kidney disease and the level of anticoagulation, with average INR 
appearing to be an important factor than the INR at the time of the event.  The 
appropriate target INR range for HMII patients should be chosen to minimize the 
risk of devastating hemorrhagic and ischemic strokes and reduce the incidence 
of major bleeding.  Since most thromboembolic events in our study occurred at 
INR <2 and the average INR in the non-bleeding population was 2.09 (compared 
to 2.47 in the bleeding population), keeping INR values in the lower therapeutic 
range seems to be a reasonable strategy.  However, INR management may best 
be tailored on an individual basis.  
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